Valuation: Candel Therapeutics, Inc.

Market Cap 637M 571M 525M 476M 889M 60.52B 906M 6.26B 2.51B 31.84B 2.39B 2.34B 100B P/E 2026 *
-5.9x
P/E 2027 * -7.16x
Enterprise Value 637M 571M 525M 476M 889M 60.52B 906M 6.26B 2.51B 31.84B 2.39B 2.34B 100B EV / Sales 2026 *
-
EV / Sales 2027 * 15.2x
Free-Float
85.21%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Candel Therapeutics, Inc.

1 day-3.70%
1 week+3.74%
Current month-20.21%
1 month-20.21%
3 months-15.60%
6 months+34.79%
Current year+47.43%
1 week 7.7
Extreme 7.7
8.93
1 month 7.7
Extreme 7.7
10.45
Current year 4.44
Extreme 4.44
14
1 year 4.35
Extreme 4.35
14
3 years 0.66
Extreme 0.66
14.6
5 years 0.66
Extreme 0.66
14.6
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 01/09/2020
Director of Finance/CFO 41 12/01/2024
Chief Tech/Sci/R&D Officer 57 12/09/2022
Director TitleAgeSince
Director/Board Member 70 08/08/2022
Director/Board Member 80 01/09/2017
Chairman 70 15/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
30/9/26 Free

Director

380 0.0005%
30/9/26 Free

Chairman

2,189 0.0029%
30/9/26 Free

Director

1,325 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
-3.70%+3.74%+49.28%+837.01% 662M
-0.62%-1.87%+46.31%+56.99% 64.38B
+0.35%+3.20%+14.92%+84.55% 56.16B
+0.53%+1.96%+15.37%+106.81% 54.16B
-2.81%-4.31%+23.50%+50.90% 45.33B
-0.33%-1.93%+20.15%+98.45% 42.25B
+0.55%+2.31%+224.97%+942.56% 40.78B
+3.27%+47.96%+112.67%+96.48% 33.8B
+1.22%-1.44%+14.89%+47.15% 32.25B
-1.29%-2.88%+21.60%-11.92% 23.57B
Average -0.28%+4.57%+54.37%+230.90% 39.33B
Weighted average by Cap. +0.02%+3.64%+52.30%+163.12%

Financials

2026 *2027 *
Net sales - 41.92M 37.54M 34.53M 31.29M 58.48M 3.98B 59.58M 412M 165M 2.09B 157M 154M 6.6B
Net income -102M -90.95M -83.66M -75.8M -142M -9.64B -144M -998M -400M -5.07B -381M -373M -16B -92.33M -82.69M -76.06M -68.92M -129M -8.77B -131M -907M -364M -4.61B -346M -339M -14.54B
Net Debt - -
Projected Income Statement - Annual - Candel Therapeutics, Inc.
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
30/10/26 USD 8.330 -3.70% 779,507
29/10/26 USD 8.650 -0.23% 740,959
28/10/26 USD 8.670 +5.09% 663,859
27/10/26 USD 8.250 +5.91% 928,461
26/10/26 USD 7.790 -2.99% 849,302
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Candel Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.330USD
Average target price
22.11USD
Spread / Average Target
+165.44%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Candel Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CADL Stock